877 results on '"Reyal, Fabien"'
Search Results
52. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
53. Initial experience of guided magnetic marker in non-palpable breast excision: first 80 cases in a French centre
54. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific
55. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma
56. Figure S3 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
57. Supplementary Table S1 from Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast
58. Table S10 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
59. Data from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
60. Table S2 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
61. Supplementary Data from Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast
62. Supplementary Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
63. Supplementary Figure Legends 1-4 from Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
64. Data from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
65. Supplementary Table 2 from Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
66. Data from Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes
67. Supplementary Table 1 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
68. Data from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
69. Supplementary Figure Legends 1-4, Methods from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
70. Supplementary Figure 2 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
71. Supplementary Figure 3 from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
72. Supplementary Figure 4 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
73. Supplementary Table S3 from Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes
74. Supplementary Figures 1-4 from Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
75. Supplementary Figure 3 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
76. Supplementary Table 2 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
77. Supplementary Figure 3 from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
78. Supplementary Figure 5 from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
79. Supplementary Figure 1 from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
80. Supplementary Figure 2 from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
81. Supplementary Figure 4 from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
82. Supplementary Figure 2B from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
83. Supplementary Figure 1 from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
84. Supplementary Methods, Figure and Table Legends from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
85. Supplementary Figure 1 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
86. Supplementary Table 1 from Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
87. Supplementary Figure 6 from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
88. Supplementary Figure 4 from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
89. Supplementary Tables 1-8C from MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
90. Data from Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
91. Abstract P3-07-06: Comedications at Breast Cancer diagnosis impact overall survival: results from the ADRENALINE (Atlas for DRug and brEast caNcer survivAL INtEraction) study (n=235,368)
92. Abstract P3-05-40: Association of body mass index with clinicopathological features and survival in patients with primary ER+/HER2- invasive lobular breast cancer
93. Breast cancer in young women: Pathologic features and molecular phenotype
94. Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
95. Sentinel Lymph Node Biopsy in Uterine Cancer: Time for a Modern Approach
96. Association of Body Mass Index with Clinicopathological Features and Survival in Patients with Primary Invasive Lobular Breast Cancer
97. Cancer du sein après maladie de Hodgkin : une revue multidisciplinaire
98. Author Correction: New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels
99. Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer
100. Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.